Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Hematology
•
General Rheumatology
•
Dermatology
•
Pediatric Rheumatology
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
Related Questions
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
Do you consider co-prescribing hormone therapy and anticoagulation in a patient with prior DVT and uncontrollable VSM uncontrolled by non-hormonal therapies?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
What are your vaccine recommendations while patients are on biologics?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
